Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease
- First Online:
- Cite this article as:
- Vásquez Jiménez, W., González Bayón, L., García-Sabrido, J.L. et al. Clin Transl Oncol (2010) 12: 794. doi:10.1007/s12094-010-0601-x
Peritoneal Malignant Disease (PMD) is the presence of tumoral tissue on the peritoneal surface from primary tumors or tumors from other locations (e.g. digestive or gynecologic). It is a regional disease with poor prognosis when treated with repeated “debulking” and traditional systemic chemotherapy. Cytoreduction plus hyperthermic intraperitoneal chemotherapy (HIPEC) is a combined multimodal regional procedure aimed at reducing the macroscopic tumoral mass as much as possible and treating with chemotherapy the microscopic disease that is out of the scope of the surgeon. This combined treatment may change the natural history of PMD, it is translated into a higher overall survival and cancer-free survival and it offers the option of cure in selected cases. The high-complexity procedure is also associated with complications and mortality, but in similar rates as other major oncologic procedures.